Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 6/2012

01-06-2012 | Letter to the Editor

Letter to the Editor

Regarding: Kraft S, Mackler E, Schlickman P, Welch K, DePestel DD (2011) Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients. Supp Care Cancer 19;1969–1974.

Author: Kenneth V. Rolston

Published in: Supportive Care in Cancer | Issue 6/2012

Login to get access

Excerpt

To the Editor: …
Literature
1.
Kraft S, Mackler E, Schlickman P, Welch K, DePestel DD (2011) Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients. Supp Care Cancer 19:1969–1974CrossRef
2.
Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64(2):328–340PubMed
3.
Elting LS, Rubenstein EB, Rolston KV, Bodey GP (1997) Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25(2):247–259PubMedCrossRef
4.
Kullar R, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J et al (2011) High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter retrospective study. Pharmacotherapy 31(6):527–536PubMedCrossRef
5.
Tran TT, Palmer HR, Weston JS, Hirsch EB, Shah DN, Cottreau JM, et al (2011) High dose daptomycin (>mg/kg) for the treatment of non-urinary vancomycin-resistant enterococcal infections. (Abstract K-1477) IN: Proceedings of the 51st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17–20, 2011
6.
Steinrucken J, Perrottet N, Pannatier A, Borens O, Trampuz A (2011) High-dose daptomycin (>6 mg/kg) for treatment of severe infections due to staphylococci and enterococci. (Abstract K-1426) IN: Proceedings of the 51st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17–20, 2011
7.
Hall AD (2011) Evaluation of standard and high dose daptomycin versus linezolid against vancomycin-resistant Enterococcus faecium (VRE) in an in vitro model of simulated endocardial vegetations (SEV). (Abstract A2-018) IN: Proceedings of the 51st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17–20, 2011
8.
Rand KH, Houck H (2004) Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 53:530–532PubMedCrossRef
9.
Rand KH, Huck H (2002) Daptomycin synergy with rifampin against vancomycin-resistant enterococci (Abstract K-1477). In: Proceedings of the 42nd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 27–30, 2002
10.
Matar MJ, Tarrand J, Raad I, Rolston KV (2006) Colonization and infection with vancomycin-resistant Enterococcus among patients with cancer. Am J Infect Control 34:534–536PubMedCrossRef
Metadata
Title
Letter to the Editor
Regarding: Kraft S, Mackler E, Schlickman P, Welch K, DePestel DD (2011) Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients. Supp Care Cancer 19;1969–1974.
Author
Kenneth V. Rolston
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 6/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1419-6

Other articles of this Issue 6/2012

Supportive Care in Cancer 6/2012 Go to the issue

Original Article

Barriers to rehabilitative care for young breast cancer survivors: a qualitative understanding

Review Article

A systematic review of the effectiveness of qigong exercise in supportive cancer care

Original Article

Critical illness-related corticosteroid insufficiency in cancer patients

Original Article

Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial

Original Article

Effect of advanced cancer patients’ awareness of disease status on treatment decisional conflicts and satisfaction during palliative chemotherapy: a Korean prospective cohort study

Original Article

Utilization of hypnotic medication in the context of cancer: predictors and frequency of use
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits